| Analysis: New rules won't put home healthcare on life support Tue,12 Jul 2011 06:23 PM PDT Reuters -  BANGALORE (Reuters) - U.S. home health service providers will remain under pressure in the near term as newly introduced rules and reimbursement rate cuts squeeze margins, but the tide should turn in 2012 as the regulatory uncertainty clears up. |
 NEW YORK (Reuters) - Mississippi Attorney General Jim Hood filed a lawsuit on Tuesday to force Kenneth Feinberg, administrator of BP's $20 billion fund for Gulf Coast oil spill compensation, to release documents it says it needs to ensure claimants are adequately compensated. | |
| Trial size may limit use of Seattle Genetics drug Tue,12 Jul 2011 01:55 PM PDT Reuters - WASHINGTON (Reuters) - U.S. drug reviewers might limit the use of a SeattleGenetics Inc experimental blood cancer drug due to the narrow scope of its clinical trials, sending the company's shares down 3.6 percent. Full Story | |
| FDA proposes targeted drug testing guidelines Tue,12 Jul 2011 01:30 PM PDT Reuters - WASHINGTON (Reuters) - Targeted drugs or therapies up for regulatory approval would have to be reviewed simultaneously with the diagnostic devices they rely on, according to a proposed policy issued on Tuesday. Full Story | |
| More kids see dentists when Medicaid rates rise Tue,12 Jul 2011 01:28 PM PDT Reuters - NEW YORK (Reuters Health) - Higher payments to dentists who treat kids on Medicaid translate into more of those kids getting regular teeth cleaning, according to a new study. Full Story | |
| Blacks in nursing homes have higher risk of sores Tue,12 Jul 2011 01:27 PM PDT Reuters - NEW YORK (Reuters Health) - Black nursing home residents are more likely than white residents to develop blisters and sores that can eventually lead to muscle and bone damage, according to a new study. Full Story | |
| Kids respond better to early "lazy eye" treatment Tue,12 Jul 2011 01:25 PM PDT Reuters - NEW YORK (Reuters Health) - Treating "lazy eye" is more likely to be successful the younger the child, but even older kids can benefit more than was previously believed, according to a large new study. Full Story | |
| FDA proposes targeted drug testing guidelines Tue,12 Jul 2011 12:09 PM PDT Reuters - WASHINGTON (Reuters) - Targeted drugs or therapies up for U.S. regulatory approval would have to be reviewed simultaneously with the diagnostic devices they rely on, according to a proposed policy issued on Tuesday. Full Story | |
| Analysis: New rules won't put home healthcare on life support Tue,12 Jul 2011 11:02 AM PDT Reuters - BANGALORE (Reuters) - Home health service providers will remain under pressure in the near term as newly introduced rules and reimbursement rate cuts squeeze margins, but the tide should turn in 2012 as the regulatory uncertainty clears up. Full Story | |
 LOS ANGELES (Reuters) - Men who are diagnosed with cancer are more likely to die from the disease than women, due to a higher initial risk and later detection, U.S. government research showed. | |
| U.N. says struggling with growing Somali exodus Tue,12 Jul 2011 09:31 AM PDT Reuters - GENEVA (Reuters) - The United Nations said on Tuesday it was struggling to keep up with an exodus of hungry Somali refugees and many emaciated children were dying of malnutrition along the way or after arriving in neighboring countries. Full Story | |
| Placebo effect seen in treating colds Tue,12 Jul 2011 09:30 AM PDT Reuters - NEW YORK (Reuters Health) - People who believe a cold remedy will work may indeed feel better sooner -- even if they don't get the real treatment, a new study suggests.Full Story | |
 HONG KONG (Reuters) - Scientists in Japan said on Wednesdaythey have created teeth -- complete with connective fibers and bones -- by using mouse stem cells and successfully transplanted them into mice, a step they hope will lead to progress in stem cell research. | |
| FDA eyes trial size for Seattle Genetics cancer drug Tue,12 Jul 2011 08:25 AM PDT Reuters - WASHINGTON (Reuters) - Seattle Genetics' experimental cancer drug showed promise in treating two rare types of blood cancer, but the design and size of clinical trials limited conclusions, U.S. drug reviewers said. Full Story | |
 CHICAGO (Reuters) - Academic and industry experts said on Tuesday they have convinced U.S. regulators to ease safety restrictions imposed on clinical trials of Alzheimer's drugs, a move that could improve the chances that a drug being developed jointly by Pfizer and Johnson & Johnson might succeed. |
No comments:
Post a Comment